Activity Overview
This online, on-demand virtual symposium brings together renowned experts in early-stage and advanced breast cancer. In this educational program, these experts use real-world patient scenarios to provide practical guidance and explore clinical controversies.
This educational activity is an archive of the live symposium held on March 6, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers involved in the treatment and management of patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret ctDNA and molecular residual disease (MRD) data from clinical trials to inform patient-centered decision-making in early-stage and metastatic breast cancer
- Apply evidence from ctDNA-guided studies to determine when liquid biopsy testing may appropriately inform clinical decision-making in breast cancer
Neil M. Iyengar, MD
Associate Professor, Department of Hematology and Medical
Oncology
Co-Director, Breast Medical Oncology, Department of Hematology and
Medical Oncology
Director, Cancer Survivorship Services, Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA
Disclosures: Consultant/Advisor: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics; Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health; Editorial Position: npj Breast Cancer, Oncology®; Equity/Ownership: Complement Theory, Bettering Company; Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat’s Ribbon of Hope, National Cancer Institute/National Institutes of Health; Contracted Research: Novartis, SynDevRx
Kelly Elizabeth McCann, MD, PhD
Assistant Clinical Professor
David Geffen School of Medicine
Jonsson Comprehensive Cancer Center
UCLA Hematology and Oncology
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Arvinas, AstraZeneca, BioNTech, Biotheranostics, Biovica, Daiichi Sankyo, Eli Lilly, Halda Therapeutic OpCo, Novartis, Pfizer, Puma Biotech, Sermonix, Stemline, Summit Therapeutics, TerSera; Speakers Bureau: Eli Lilly; Grant/Research Funding: Ambrx, AstraZeneca, BriaCell, Duality Biologics, Eli Lilly, G1 Therapeutics, Gilead, H3 Biomedicine, Immunomedics, MacroGenics, Marengo Therapeutics, Merck, Novartis, Olema, Pfizer, Puma Biotech, Roche/Genentech, Sanofi, Stemline, Zymeworks
Wassim Mchayleh, MD, MBA, FACP
Medical Director, Breast Oncology
AdventHealth Cancer Institute
Orlando, FL
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, DSI, Eli Lilly and Company, Gilead Sciences, Merck, SAGA, Stemline; Speakers Bureau: AstraZeneca, DSI, Eli Lilly and Company, Gilead Sciences, Merck, Stemline
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here